Thyroid Eye Disease: Multidisciplinary Management of Ocular Surface Disease and Considerations for Cataract/Refractive Surgery (Online CME Monograph)
Activity Description and Purpose
This educational activity aims to provide clinicians with advanced knowledge and competence in identifying the relationship between thyroid eye disease (TED) and comorbid ocular conditions, with a focus on dry eye disease (DED) and ocular surface disease (OSD). Topics covered in this activity include differential diagnoses for TED in patients with proptosis, how DED and OSD overlap, and data on medications used to treat TED. This educational activity integrates didactic content with clinical case studies and panel discussions with experts to reinforce best practices in the management of TED in patients with DED and OSD. At the completion of this activity, clinicians will understand how to effectively position themselves within the multidisciplinary team to achieve positive outcomes in patients with TED and DED and OSD. The desired results of this activity are to increase appropriate treatment of TED in practice and to foster competent interdisciplinary collaboration to ensure the best possible outcomes for patients with TED.
Target Audience
This educational activity is intended for cataract/refractive surgeons, cornea specialists, ophthalmologists, oculoplastic surgeons, and neuro-ophthalmologists.
Learning Objectives
After completing this activity, participants will be better able to:
- Identify the relationship between thyroid eye disease and comorbid ocular conditions
- Review clinical data on treatments for thyroid eye disease that will help inform referral practices
- Apply best practices to cases involving comorbid ocular conditions
Faculty
Kenneth A. Beckman, MD, FACS (Chair) Clinical Assistant Professor of Ophthalmology Ohio State University Columbus, Ohio Director of Corneal Surgery Comprehensive Eye Care of Central Ohio Westerville, Ohio | |
Deepinder K. Dhaliwal, MD, LAc Professor of Ophthalmology University of Pittsburgh School of Medicine Vice Chair Department of Ophthalmology, Communications and Wellness Chief of Refractive Surgery, UPMC Vision Institute Director and Founder, Center for Integrative Eye Care Clinical Co-Director, Corneal Stem Cell Task Force Associate Medical Director, Charles T. Campbell Ocular Microbiology Laboratory Medical Director, UPMC Laser Vision Center Pittsburgh, Pennsylvania | |
Wendy W. Lee, MD, MS Professor of Clinical Ophthalmology and Dermatology Oculofacial Plastic & Reconstructive Surgery, Orbit, and Oncology Bascom Palmer Eye Institute University of Miami Miller School of Medicine Miami, Florida |
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Kenneth A. Beckman, MD, is a consultant for AbbVie Inc, Alcon, Amgen, Bausch & Lomb Incorporated, Bruder Healthcare, BVI, Dompé US, Inc, Glaukos Corporation, Invirsa Ic, Johnson & Johnson Vision Care, Inc*, Novartis Pharmaceuticals Corporation*, Ocular Science, Shenyang Sinqi Pharmaceutical Co, Ltd, Sun Pharmaceutical Industries, Inc*, Thea Pharma Inc, Trukera Medical, Verséa Health, Inc, Viatris Inc, Visus Therapeutics, and Yuyu Pharma, Inc; is a contracted researcher for Glaukos Corporation; and has stocks or stock options in RxSIGHT*.
Deepinder K. Dhaliwal, MD, LAc, is a consultant for Haag-Streit Group and Tarsus Pharmaceuticals, Inc; is an advisory board member of Bausch & Lomb Incorporated, CSI Dry Eye Software, EyeYon, LENZ Therapeutics, Inc, STAAR Surgical, TearSolutions, and Trefoil Therapeutics; and is a contracted researcher for Amber Ophthalmics, Bausch & Lomb Incorporated, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, and Kyruus, Inc.
Wendy W. Lee, MD, MS, is a consultant for AbbVie Inc, Amgen Inc, Novabay Pharmaceuticals, Inc, Revance Therapeutics, Inc, RVL Pharmaceuticals, Inc*, and Tarsus Pharmaceuticals, Inc; and is a contracted researcher for Viridian Therapeutics, Inc.
Consulting Contributor for Table 3
Sonalika Khachikian, MD, is a consultant for Amgen Inc; is on the speakers bureau for Amgen Inc; and is on the advisory board of Amgen Inc.
Peer Reviewer
Hadi Kaakour, MD, has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
* The financial relationship existed during the past 24 months but has now ended
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Amgen Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs or devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Amgen Inc.
This CME activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 323.1
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation